The Extracellular Matrix (ECM) Symposium with a focus on drug discovery and development will take place next year: March 2021. We are celebrating 500 publications with a two half-day symposium on ECM. We will take deep dives in lung fibrosis (IPF), liver fibrosis (NASH), inflammatory bowel diseases (UC and Crohn’s), solid cancers with tissue fibrosis, inflammatory joint diseases (RA, OA, PSA), systemic sclerosis (SSC), kidney fibrosis (CKD, DKD) and heart failure (CVD) which all are diseases with dysfunctional fibroblasts and altered ECM. We are very proud to present Dr. Mina Bissell, a renowned biologist and ECM research expert, who will give a talk reflecting on the importance of the ECM. The almost-final program is attached. We are presenting the program with University of Southern Denmark (SDU), where I am an adjunct professor. We hope that many students will join. Not just from SDU but other universities, companies and people interested in the ECM. You are welcome to sign up now at ECMsymposium@nordicbio.com, and send an abstract. We will select two abstracts for oral presentations and awards. We cannot wait to host this special event. Please join us keeping the scientific buzz going in this challenging period for so many individuals. Stay safe and Happy Holidays, Prof. Morten Karsdal, CEO Nordic Bioscience
The production cycle from antibody-design to assay production is a collaboration between the research groups in RnD (and a potential sponsor) and the Antibody Research Unit (ARU) and the Technology Evaluation and Automation (TEA) group, which helps to facilitate and streamline the antibody development and assay production in RnD. There is a large degree of communication between the individual research groups and ARU and TEA to ensure the best design and development of our assays, as well as an thorough and precise final validation before the assay is transferred to our GMP production for large-scale manufacturing.
Meet Anne Christine Bay-Jensen, Director, ImmunoScience. Anne started working at Nordic Bioscience in 2008. Anne is the daily leader of 20 scientists and technicians. Her main focus area is development, test and validation of biomarkers for translational science, drug development and personalized medicine.
Meet Federica Genovese, Director of Fibrosis, Renal and Cardiovascular Research. Federica joined the company in 2011, with a background as a PhD in biochemistry and an MSc in biotechnology. At Nordic, she focuses on the biomarker discovery and development of extracellular matrix remodeling in fibrosis.
Meet Diana Julie Leeming, Director of Fibrosis, and daily manager of 15 scientists and technicians developing the next generation of biomarkers at Nordic Bioscience. Diana has been working 14 years with Nordic Bioscience, 7 years with research in osteoporosis, and now in her 8th year in fibrosis.
Please don't hesitate to contact us if you have any questions or other inquiries.